83 related articles for article (PubMed ID: 29464077)
1. Complement C4d-specific antibodies for the diagnosis of lung cancer.
Ajona D; Okrój M; Pajares MJ; Agorreta J; Lozano MD; Zulueta JJ; Verri C; Roz L; Sozzi G; Pastorino U; Massion PP; Montuenga LM; Blom AM; Pio R
Oncotarget; 2018 Jan; 9(5):6346-6355. PubMed ID: 29464077
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis of pulmonary nodules by DNA methylation analysis in bronchoalveolar lavage fluids.
Li L; Ye Z; Yang S; Yang H; Jin J; Zhu Y; Tao J; Chen S; Xu J; Liu Y; Liang W; Wang B; Yang M; Huang Q; Chen Z; Li W; Fan JB; Liu D
Clin Epigenetics; 2021 Oct; 13(1):185. PubMed ID: 34620221
[TBL] [Abstract][Full Text] [Related]
3. Clinical validation of a blood-based classifier for diagnostic evaluation of asymptomatic individuals with pulmonary nodules.
Birse CE; Tomic JL; Pass HI; Rom WN; Lagier RJ
Clin Proteomics; 2017; 14():25. PubMed ID: 28694742
[TBL] [Abstract][Full Text] [Related]
4. Risk assessment for indeterminate pulmonary nodules using a novel, plasma-protein based biomarker assay.
Trivedi NN; Arjomandi M; Brown JK; Rubenstein T; Rostykus AD; Esposito S; Axler E; Beggs M; Yu H; Carbonell L; Juang A; Kamer S; Patel B; Wang S; Fish AL; Haddad Z; Wu AH
Biomed Res Clin Pract; 2018 Dec; 3(4):. PubMed ID: 32913898
[TBL] [Abstract][Full Text] [Related]
5. Curating retrospective multimodal and longitudinal data for community cohorts at risk for lung cancer.
Li TZ; Xu K; Chada NC; Chen H; Knight M; Antic S; Sandler KL; Maldonado F; Landman BA; Lasko TA
Cancer Biomark; 2024 Mar; ():. PubMed ID: 38517780
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and management of indeterminate liver nodules in patients with cirrhosis.
Kanneganti M; Singal AG
Clin Liver Dis (Hoboken); 2023 Nov; 22(5):181-183. PubMed ID: 38026118
[No Abstract] [Full Text] [Related]
7. Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges.
Seijo LM; Peled N; Ajona D; Boeri M; Field JK; Sozzi G; Pio R; Zulueta JJ; Spira A; Massion PP; Mazzone PJ; Montuenga LM
J Thorac Oncol; 2019 Mar; 14(3):343-357. PubMed ID: 30529598
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive biomarkers for lung cancer diagnosis, where do we stand?
Kammer MN; Massion PP
J Thorac Dis; 2020 Jun; 12(6):3317-3330. PubMed ID: 32642255
[TBL] [Abstract][Full Text] [Related]
9. Humoral complementomics - exploration of noninvasive complement biomarkers as predictors of renal cancer progression.
Revel M; Rezola Artero M; Hamidi H; Grunenwald A; Blasco L; Vano YA; Marie Oudard S; Sanchez-Salas R; Macek P; Rodriguez Sanchez L; Cathelineau X; Vedié B; Sautes-Fridman C; Herman Fridman W; Roumenina LT; Dragon-Durey MA
Oncoimmunology; 2024; 13(1):2328433. PubMed ID: 38487624
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers of lung cancer for screening and in never-smokers-a narrative review.
Stephens EKH; Guayco Sigcha J; Lopez-Loo K; Yang IA; Marshall HM; Fong KM
Transl Lung Cancer Res; 2023 Oct; 12(10):2129-2145. PubMed ID: 38025810
[TBL] [Abstract][Full Text] [Related]
11. Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics.
Padinharayil H; Varghese J; John MC; Rajanikant GK; Wilson CM; Al-Yozbaki M; Renu K; Dewanjee S; Sanyal R; Dey A; Mukherjee AG; Wanjari UR; Gopalakrishnan AV; George A
Genes Dis; 2023 May; 10(3):960-989. PubMed ID: 37396553
[TBL] [Abstract][Full Text] [Related]
12. Update on Biomarkers for the Stratification of Indeterminate Pulmonary Nodules.
Paez R; Kammer MN; Tanner NT; Shojaee S; Heideman BE; Peikert T; Balbach ML; Iams WT; Ning B; Lenburg ME; Mallow C; Yarmus L; Fong KM; Deppen S; Grogan EL; Maldonado F
Chest; 2023 Oct; 164(4):1028-1041. PubMed ID: 37244587
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers in Lung Cancer Screening: a Narrative Review.
Marmor HN; Zorn JT; Deppen SA; Massion PP; Grogan EL
Curr Chall Thorac Surg; 2023 Feb; 5():. PubMed ID: 37016707
[TBL] [Abstract][Full Text] [Related]
14. Clinical Scores, Biomarkers and IT Tools in Lung Cancer Screening-Can an Integrated Approach Overcome Current Challenges?
Voigt W; Prosch H; Silva M
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831559
[TBL] [Abstract][Full Text] [Related]
15. Bronchoalveolar Lavage Fluid-Isolated Biomarkers for the Diagnostic and Prognostic Assessment of Lung Cancer.
Kalkanis A; Papadopoulos D; Testelmans D; Kopitopoulou A; Boeykens E; Wauters E
Diagnostics (Basel); 2022 Nov; 12(12):. PubMed ID: 36552956
[TBL] [Abstract][Full Text] [Related]
16. C5a elevation in convalescents from severe COVID-19 is not associated with early complement activation markers C3bBbP or C4d.
Kowalska D; Kuźniewska A; Senent Y; Tavira B; Inogés S; López-Díaz de Cerio A; Pio R; Okrój M; Yuste JR
Front Immunol; 2022; 13():946522. PubMed ID: 36091057
[TBL] [Abstract][Full Text] [Related]
17. Advances in lung cancer screening and early detection.
Li C; Wang H; Jiang Y; Fu W; Liu X; Zhong R; Cheng B; Zhu F; Xiang Y; He J; Liang W
Cancer Biol Med; 2022 May; 19(5):591-608. PubMed ID: 35535966
[TBL] [Abstract][Full Text] [Related]
18. The impact of the lung EDRN-CVC on Phase 1, 2, & 3 biomarker validation studies.
Kammer MN; Deppen SA; Antic S; Jamshedur Rahman SM; Eisenberg R; Maldonado F; Aldrich MC; Sandler KL; Landman B; Massion PP; Grogan EL
Cancer Biomark; 2022; 33(4):449-465. PubMed ID: 35491773
[TBL] [Abstract][Full Text] [Related]
19. A Cost-Effectiveness Analysis of Lung Cancer Screening With Low-Dose Computed Tomography and a Diagnostic Biomarker.
Toumazis I; Erdogan SA; Bastani M; Leung A; Plevritis SK
JNCI Cancer Spectr; 2021 Dec; 5(6):. PubMed ID: 34738073
[TBL] [Abstract][Full Text] [Related]
20. Molecular biomarkers in early stage lung cancer.
Rodríguez M; Ajona D; Seijo LM; Sanz J; Valencia K; Corral J; Mesa-Guzmán M; Pío R; Calvo A; Lozano MD; Zulueta JJ; Montuenga LM
Transl Lung Cancer Res; 2021 Feb; 10(2):1165-1185. PubMed ID: 33718054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
